Kirsten L. Gruis - 01 Jun 2023 Form 4 Insider Report for DiaMedica Therapeutics Inc. (DMAC)

Reporting relationship: Chief Medical Officer
Issuer ticker: DMAC
Reported as of: 01 Jun 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 Jun 2023, 16:55:43 UTC
Prior SEC filing: 05 Jan 2022
Source filing: View source filing
Reporting owner signature: /s/ Amy E. Culbert, attorney-in-fact

Key filing fact

Kirsten L. Gruis filed Form 4 for DiaMedica Therapeutics Inc. (DMAC) on 02 Jun 2023.

Key facts

This page summarizes Kirsten L. Gruis's Form 4 filing for DiaMedica Therapeutics Inc. (DMAC).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 Jun 2023, 16:55.

Change

Previous filing in this sequence was filed on 05 Jan 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

DMAC holding

Voting Common Shares, no par value per share

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 0
Date: 01 Jun 2023
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

DMAC transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +67,000
Change %
Price: $0.000000
Shares after: 67,000
Date: 01 Jun 2023
Ownership: Direct
Underlying class: Common Shares
Underlying amount: 67,000
Exercise price: $2.73
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Vests with respect to 25% of the underlying common shares on June 1, 2024 and with respect to the remaining 75% of the underlying common shares vesting quarterly over the following three years commencing on September 1, 2024.